CD274 and non-small cell lung carcinoma: The phase II CITYSCAPE study evaluated tiragolumab plus atezolizumab versus placebo plus atezolizumab as first-line treatment in patients with PD-L1-positive EGFR/ALK wild-type locally advanced or metastatic NSCLC.